Company: DMAAR
Filing Date: 2025-01-22
Form Type: POS AM
Source: 0001213900-25-005176
Chunk: 25

Company: Drugs Made In America Acquisition Corp.
Filing Date: 2025-01-22
Form: POS AM
Chunk 25
---
 redeem 100% of the issued and outstanding public shares at a per share price, payable in cash, equal to the aggregate amount then on deposit in the trust account, including interest (net of amounts withdrawn to pay our taxes, if any, and up to $100,000 of interest to pay dissolution expenses), divided by the number of then issued and outstanding public shares, subject to applicable law and certain conditions and as further described herein; •“directors” are to our current directors and our director nominees named in this prospectus; •“equity -linkedsecurities” are to any debt or equity securities that are convertible, exercisable or exchangeable for our ordinary shares issued in a financing transaction in connection with our initial business combination, including but not limited to a private placement of equity or debt securities; •“founder shares” are to our ordinary shares initially purchased by our sponsor in a private placement prior to this offering; •“initial shareholders” are to our sponsor and any other holders of our founder shares immediately prior to this offering (including Lynn Stockwell, the managing member of the sponsor, and Glenn Worman, Catherine Do, G. Sridhar Prasad and Myron W. Shulgan who will receive an aggregate of 400,000 founder shares from our sponsor); •“letter agreement” are to the letter agreement, the form of which is filed as an exhibit to the registration statement of which this prospectus forms a part; •“management” or our “management team” are to our directors and officers; •“memorandum and articles of association”are to our current Amended and Restated Memorandum and Articles of Association; •“non -managingsponsor investors” means two institutional investors (none of which are affiliated with any member of our management, other members of our sponsor or any other investor) that have expressed an interest to purchase (i) up to an aggregate of approximately $39.8million of the units in this offering (assuming the exercise in full of the underwriters’ over -allotmentoption) at the offering price and (ii) indirectly, through the purchase of non -managingsponsor membership interests an aggregate of 50,000 of the 400,000 private placement units (or 430,000 private placement units if the underwriters’ over -allotmentoption is exercised in full) being purchased by our sponsor at a price of $10.00 per unit ($500,000 in the aggregate); subject to each non -